|
|
||||||||
Division of Metabolism and Endocrine Drug Products, Office of Biologics Research and Review, and the Division of Epidemiology and Surveillance, Office of Epidemiology and Biostatistics, Center for Drugs and Biologics, Food and Drug Administration, Rockville, MD.
Creutzfeldt-Jakob disease (CJD) has been reported in three US patients previously treated with human growth hormone derived from large pools of human cadaver pituitary glands (pit-hGH). Neurologic disorders other than CJD occurred in 10 growth hormone-deficient patients treated with pit-hGH. These 10 cases could have been chance events or true syndromes; some cases may have been caused by transmissible agents contained in the pooled growth hormone product.
Address correspondence and reprint requests to Dr. Rappaport, New Jersey State Department of Health, Special Child Health Services Program, CN 364, Trenton, NJ 08625.
Received June 5, 1986. Accepted for publication in final form October 14, 1986.
This article has been cited by other articles:
![]() |
A. K. Shetty and R. W. Steele Commentary Review: Prion Diseases Clinical Pediatrics, January 1, 1997; 36(1): 1 - 7. [PDF] |
||||
![]() |
R. C. Green, J. Green, J. M. Harrison, and M. H. Kutner Screening for Cognitive Impairment in Older Individuals: Validation Study of a Computer-Based Test Arch Neurol, August 1, 1994; 51(8): 779 - 786. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |